The panel answers questions from the audience at the ESH 2021 satellite symposium providing insight into treatment considerations with different Bruton's tyrosine kinase inhibitors (BTKis) for Waldenström's macroglobulinemia (WM) patients.

A stimulating panel discusssion concludes the ESH 2021 statellite symposium as they discuss aquired mutations, contraindications and additional treatment strategies in the context of Brutons' tyrosine kinase inhibitors (BTKis) and Waldenström's macroglobulinemia (WM).

Professor Steven Treon outlines the impact of the MYD88^L265P mutation on the toll-like receptor (TLR) signalling pathway and explains how Bruton's tyrosine kinase (BTK) inhibitors can be used to target the pathway.

Professor Christian Buske provides guidelines for the management of non-Hodgkin's lymphomas (NHLs) and specifically Waldenström's macroglobulinemia (WM) during the COVID-19 pandemic.

Professor Marie José Kersten summarizes the relevant factors to be considered when deciding the treatment strategy for Waldenström's macrogloublinemia (WM) patients.